Cargando…
Response and safety of whole‐brain radiotherapy plus temozolomide for patients with brain metastases of non‐small‐cell lung cancer: A meta‐analysis
OBJECTIVE: The aim of the present work was to investigate the response and safety of whole‐brain radiotherapy (WBRT) plus temozolomide (TMZ) for patients with brain metastases of non‐small‐cell lung cancer (NSCLC). METHODS: The electronic databases of Pubmed, EMbase, Cochrane, Wangfang, china nation...
Autores principales: | Han, Jianguo, Qiu, Ming, Su, Li, Wu, Chong, Cheng, Si, Zhao, Zhijun, Li, Danxia, Wang, Menghui, Tao, Wei, Du, Shiwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636221/ https://www.ncbi.nlm.nih.gov/pubmed/34704360 http://dx.doi.org/10.1111/1759-7714.14183 |
Ejemplares similares
-
Meta‐analysis of whole‐brain radiotherapy plus temozolomide compared with whole‐brain radiotherapy for the treatment of brain metastases from non‐small‐cell lung cancer
por: Xin, Yong, et al.
Publicado: (2018) -
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis
por: Zhao, Qian, et al.
Publicado: (2016) -
Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases
por: Zhu, Ying, et al.
Publicado: (2018) -
Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
por: Duan, Hua, et al.
Publicado: (2020) -
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)